Henry R. Kravis
Co-Executive Chairman at KKR & Co. Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2024
3 years of board service in total across 1 board, counting each seat separately. Longest: KKR & Co. Inc., 2 years.
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 5, 2026 | BrightSpring Health Services Inc. | Open-market sale | −14,669,771 | $58.45 | $857,448,115 |
| Jun 5, 2026 | BrightSpring Health Services Inc. | Other | −324,608 | — | — |
| Jun 5, 2026 | BrightSpring Health Services Inc. | Gift | −36,927 | — | — |
| Jun 5, 2026 | BrightSpring Health Services Inc. | Gift | −23,263 | — | — |
| Nov 12, 2025 | KKR & Co. Inc. | Gift | −350,000 | — | — |
| Oct 22, 2025 | BrightSpring Health Services Inc. | Open-market sale | −14,745,000 | $28.78 | $424,361,100 |
| Oct 22, 2025 | BrightSpring Health Services Inc. | Other | −409,305 | — | — |
| Oct 22, 2025 | BrightSpring Health Services Inc. | Gift | −50,484 | — | — |
| Oct 22, 2025 | BrightSpring Health Services Inc. | Gift | −39,493 | — | — |
| Jun 2, 2025 | KKR & Co. Inc. | Open-market sale | −1,150,469 | $119.80 | $137,826,186 |
| Jun 2, 2025 | KKR & Co. Inc. | Open-market sale | −130,925 | $121.67 | $15,929,645 |
| May 15, 2025 | KKR & Co. Inc. | Other | −250,377 | — | — |
| May 12, 2025 | BridgeBio Pharma Inc. | Open-market sale | −6,000,000 | $34.20 | $205,200,000 |
| Mar 13, 2025 | KKR & Co. Inc. | Gift | −208,676 | — | — |
| Nov 21, 2024 | Applovin Corporation | Derivative conversion | +5,205,489 | — | — |
Questions about Henry R. Kravis
What boards is Henry R. Kravis on?
Henry R. Kravis sits on the board of KKR & Co. Inc.
How long has Henry R. Kravis served on boards?
Our records show at least 3 years of board service across 1 board, the earliest from 2024.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.